A/Prof Sasha Senthi

Radiation Oncologist
Become a Patient

A/Prof Sasha Senthi is a leading radiation oncologist with practices across Melbourne. He supports patients with the latest radiation therapy techniques, in particular stereotactic radiation therapy, to personalise care and achieve the best possible outcome. He gives hope to his patients and prioritises their quality of life throughout their cancer journey. A/Prof Senthi is here to help and welcomes any direct contact on his mobile 0407 834 663.


A/Prof Sasha Senthi is a senior radiation oncologist who consults and treats patients at multiple Icon Cancer Centre locations across Victoria including Epworth Richmond, Epworth Freemasons, Mulgrave, Holmesglen and Warrnambool. He welcomes patients connecting with him directly and will respond within 24 hours.

A/Prof Senthi attained his Bachelor of Human Biology (BHB) and Bachelor of Medicine, Bachelor of Surgery (MBChB) at the University of Auckland and completed radiation oncology training at Peter MacCallum Cancer Centre. He also holds a Master of Public Health from Harvard University.

A/Prof Senthi is the first Australian to undertake a fully funded clinical research fellowship in stereotactic radiation therapy at VU Medical Centre (VUMC) in Amsterdam, where he completed his PhD. In 2016 he was awarded the Victorian Cancer Agency’s clinical research fellowship and started a laboratory to optimise the combination of immunotherapy and stereotactic radiation therapy.

He is closely involved in clinical research, quality assurance and medical education. A/Prof Senthi is a Trans Tasman Radiation Oncology Group (TROG) board member and TROG Scientific Committee Chair. This group oversees and prioritises radiation therapy research in Australia and New Zealand. As an Associate Professor at Monash University he actively supervises and mentors emerging medical professionals and PhD students in both the clinical and laboratory setting. A/Prof Senthi has published several world-first radiation therapy studies and abstracts in leading peer-reviewed journals, defining the field of radiation oncology.

A/Prof Senthi treats a broad range of malignancies with a special interest in brain cancer, spinal (CNS) cancers, oligometastatic (stage IV) cancer, lung cancer and skin cancers, including melanoma. He is recognised expert in the most advanced radiation therapy techniques, in particular stereotactic radiation therapy (also known as radiosurgery, SABR or SBRT).

Affiliations & Memberships

  • American Society of Clinical Oncology (ASCO)
  • American Society for Radiation Oncology (ASTRO)
  • European Society for Radiotherapy and Oncology (ESTRO)
  • Royal Australian and New Zealand College of Radiologists (RANZCR)
  • Trans Tasman Radiation Oncology Group (TROG)

Special Interests

A/Prof Sasha Senthi accepts referrals for all cancer types with a special clinical interest in:
  • Brain and spine (CNS) cancer
  • Gastrointestinal cancer
  • Lung cancer
  • Melanoma
  • Stereotactic radiation therapy

Icon Locations

Mulgrave View centre
Epworth Richmond View centre
Epworth Freemasons View centre
Holmesglen View centre
Warrnambool View centre


  • Palma, D., Senthi, S. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABRCOMET): a randomised, phase 2, open-label trial. The Lancet 393.10185 (2019): 20251-2058.

  • Senthi, S. et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. The Lancet Oncology 13.8 (2012): 802-809.

  • Senthi, S. et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiotherapy and Oncology 106.3 (2013): 276-282.

  • Senthi, S. et al. Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes. Journal of thoracic disease 5.2 (2013): 116.

  • Huang, K. Senthi S. et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiotherapy and Oncology 109.1 (2013): 51-57.